Infant mortality rate is an important indicator of population health. A 2017 report from the US Centers for Disease Control and Prevention 1 reported that the infant mortality rate in the United States decreased by 15% in the past decade. The objective of this study is to establish if both black and white infants benefitted equally from this decrease. We investigated recent trends in the absolute difference in overall and cause-specific infant mortality rates between non-Hispanic black and white infants.
Methods | In this repeated cross-sectional study, we abstracted data on live births and deaths in the first year of life for non-Hispanic black and white infants from the US National Vital Statistics System from 2005 to 2015. The infant mortality rate was calculated as the number of deaths (mortality file) 2 divided by the number of births (natality file), 3 according to race/ethnicity, year, and cause of death. We calculated rates for the top 4 causes of infant death and a residual category encapsulating all other causes. The excess event rate among black infants was calculated as the absolute difference between the rates. We did not include confidence intervals because these rates are not subject to sampling error. 4 R version 3.2.4 (The R Foundation) was used to conduct the analysis. Institutional review board approval was waived because the study used deidentified, publicly available data, and informed consent was not required. A replication data set including the raw data and statistical code to reproduce the letter is publicly available on github (https://github.com /corinne-riddell/InfantMortality/).
Results | From 2005 to 2012, the infant mortality rate for nonHispanic black infants decreased from 14.3 to 11.6 per 1000 births ( Figure 1A) . Thereafter, the infant mortality rate in black infants plateaued and then increased from 11.4 to 11.7 from 2014 to 2015. For non-Hispanic white infants, the rate decreased monotonically from 5.7 to 4.8 per 1000 from 2005 to 2015. Because the black infant mortality rate declined faster than the white infant mortality rate, excess events in black infants fell from 8.6 deaths per 1000 infants in 2005 to 6.6 deaths in 2012 but rose to 6.9 in 2015 ( Figure 1B ). These excess events imply nearly 4000 additional infant deaths among the 589 047 black infants compared with the number of expected deaths if they had experienced the same mortality rate as white infants. Figure 2 shows trends in cause-specific mortality for the 4 leading causes of infant death and all other causes. Between 2005 and 2011, deaths from short gestation and low birthweight decreased for black infants but have plateaued in recent years. For other leading causes (ie, congenital malformations, sudden infant death syndrome, and maternal complications), rates among black and white infants decreased between 2005 and 2015, although deaths related to both sudden infant death syndrome and congenital malformations increased for black infants last year. Progress has stalled with respect to all other causes of infant death in recent years, and last year also saw a relatively larger increase in mortality rates for black infants compared with white infants.
Discussion | No single cause appears solely responsible for the recent increase in black infant mortality, and in many instances, some arbitrariness exists in the single cause that is assigned. The preterm birth rate is nearly 50% higher for black compared with white infants. 5 Furthermore, black infants experience nearly 4-fold as many deaths related to short gestation and low birthweight, making it the leading cause of infant death among black infants. Conclusions | The sustained progress in reducing infant mortality among black infants since 2005 has stalled in the past few years. This has led to increases in the absolute inequality in infant mortality between black and white infants during the past 3 years. Interventions to further reduce the rate of preterm birth among black infants appear the most promising option for reducing black infant mortality and the absolute inequality between black and white infants. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
COMMENT & RESPONSE Extending the Social Justice Call to Treatment Outcomes
To the Editor Kudos to Racine for calling the pediatric community to consider its role in a social justice framework. 1 His call should extend to all of us in the pediatric research community as well. Further, I propose that it is even more critical where mental health treatment of the poor may result in overtreatment. Applying John Rawls' ethical decision model to assure a just mental health treatment decision means forming a decision without knowing whether the child is poor and socially deprived or well off in a socially privileged environment or whether the caregiver is a foster parent or the pediatrician's or researcher's daughter. Most critically, a just decision may depend on the prescriber's greater proportional responsibility for a continually evolving awareness of the strengths and limitations of the pediatric pharmacologic and treatment knowledge base as treatments are used over time.
Three mental health concerns that could play a greater role in ascertaining a just mental health treatment decision include: 1. The lack of objective criteria for a mental health diagnosis results in a diagnostic and statistical manual that is primarily reliant on symptom checklists. This situation can lead to a reductionism ignoring functioning, severity, and social context and produce overdiagnosis. 2 Not surprisingly, we have seen prominent growth of medication use to treat behavioral problems in youths, particularly among poor and vulnerable youths. These patterns may be a misplaced effort to serve the underserved by conflating social deficits of the poor with mental health problems. If we had data to assure us of benefits outweighing harms, we might be justified. However, such evidence is sadly lacking. 2. The distinction between outcomes derived from shortterm, largely proprietary clinical trials and the nearly absent outcomes derived from community populations is largely ignored. 3 No wonder we generalize outcomes from highly publicized clinical trial volunteer populations to community-based "real-world" populations despite data showing that those in these communities are less white, poorer, and living in geographically disparate neighborhoods. 3. Off-label prescribing in our youths has been a timehonored authorization to physicians to try medications in youths based on efficacy and safety in adults 4 but now could be enhanced by postmarketing studies, particularly for poor youths treated with complex drug regimens.
5
Social justice arguments strengthen the rationale for a more comprehensive, outcomes-oriented assessment in realworld populations, particularly among vulnerable youths at risk for mental health overtreatment.
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